Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Protalix BioTherapeutics reported its financial results for the second quarter of 2026, revealing total revenue of $5.2 million. The company highlighted its ongoing commitment to advancing its pipeline and business operations.
Why Is Protalix BioTherapeutics Stock Falling On Friday?
Protalix BioTherapeutics to Present at Investor Summit Virtual